Group 1 - BeOne Medicines Ltd. reported $1.32 billion in revenue for the quarter ended June 2025, a year-over-year increase of 41.6% [1] - The earnings per share (EPS) for the same period was $0.84, compared to -$1.15 a year ago, indicating a significant turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $1.24 billion by 6.17%, and the EPS surprise was 75% above the consensus estimate of $0.48 [1] Group 2 - Key product revenue included BRUKINSA at $949.84 million, TEVIMBRA at $193.52 million, and total product revenue net at $1.3 billion, all surpassing analyst estimates [4] - Collaboration revenue reached $13.22 million, a 64.9% increase compared to the year-ago quarter, exceeding the average estimate of $7.59 million [4] - Other notable product revenues included KYPROLIS at $19.42 million, BLINCYTO at $25.59 million, and XGEVA at $81.32 million, all of which met or exceeded analyst expectations [4] Group 3 - BeOne Medicines Ltd. shares have returned +25.7% over the past month, significantly outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say